Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Infectious Disease · Human Immunodeficiency Virus Infection

Starting Treatment with Confidence

At a Glance

Most people with HIV should begin antiretroviral therapy as soon as possible, sometimes on the day of diagnosis. Clinicians choose the regimen and timing based on hepatitis B, kidney function, pregnancy, resistance results, prior drug exposure, and possible severe infections.

The goal of modern HIV treatment is to stop the virus from replicating, allowing your immune system to recover and preventing the progression to AIDS [1]. This is achieved through Antiretroviral Therapy (ART), a combination of medications taken daily. Today, treatment is so effective and well-tolerated that most people take just one pill once a day [2].

How Your Medications Work

Standard HIV treatment usually combines drugs from two different classes. Each class targets a different part of the virus’s machinery:

  • Integrase Strand Transfer Inhibitors (INSTIs): These are the “powerhouse” of modern regimens. They block integrase, an enzyme HIV uses to insert its genetic material into your DNA [3]. This class is preferred because it works quickly, has fewer side effects, and is very difficult for the virus to develop resistance against [4].
  • Nucleoside Reverse Transcriptase Inhibitors (NRTIs): Often called the “backbone” of your treatment, these drugs act as fake building blocks [5]. When the virus tries to build new DNA, it accidentally uses these duds, which causes the assembly process to grind to a halt [3][6].

The ‘Rapid Start’ Approach

In the past, doctors often waited weeks for lab results before starting treatment. Current medical guidelines now recommend Rapid Start—offering to start ART as soon as possible after diagnosis, sometimes even on the same day [1][7].

Research shows that starting treatment quickly leads to several benefits:

  • Faster Suppression: You reach an “undetectable” viral load sooner [8].
  • Better Engagement: People who start quickly are more likely to stay in long-term care [9].
  • Peace of Mind: Taking action immediately can help reduce the anxiety of a new diagnosis [7].

However, same-day ART is not universally appropriate. Clinicians may need to delay ART if you have symptoms of a severe central nervous system infection (like suspected cryptococcal or TB meningitis) to prevent dangerous inflammation, and they must assess pregnancy status, HBV status, and prior INSTI exposure before finalizing timing.

Examples of Initial Regimens

Initial therapy is individualized based on your renal function, HBV status, prior exposure, and lab results. Common examples include:

1. Biktarvy (Bictegravir/Emtricitabine/TAF)

This is a 3-drug, single-tablet regimen that is widely used because it can often be started before all lab results are back, though pending HBV and resistance results must still be accounted for [2]. It is highly effective and carries a very high “barrier to resistance,” meaning it is hard for the virus to bypass it [10][11].

2. Dovato (Dolutegravir/Lamivudine)

This is a 2-drug, single-tablet regimen. While it is just as effective as 3-drug options for most people, it has strict requirements for use [12]. It is generally avoided if:

  • You have active Hepatitis B (HBV), as it does not contain enough medication to treat both viruses [13][14].
  • Your initial viral load is very high (over 500,000 copies/mL) [15].
  • You are pregnant or planning to become pregnant; while dolutegravir itself is widely recommended in pregnancy, you should consult an HIV/perinatal specialist regarding this specific 2-drug regimen [16].

3. Triumeq (Dolutegravir/Abacavir/Lamivudine)

This 3-drug regimen is another potent option, but it is not generally a preferred first-line option for most people. It requires a specific genetic test called HLA-B*57:01 [17]. If you have this genetic marker, you cannot take this medication because of the risk of a severe allergic reaction [18]. It also requires additional medications if you have Hepatitis B [19], and requires careful consideration of your kidney function and cardiovascular risk.

The Power of Adherence and Interactions

For ART to work, it must be taken every single day. Consistent “adherence” keeps enough medicine in your bloodstream to keep the virus completely suppressed [1].

If doses are frequently missed, the level of medicine drops, giving the virus a chance to mutate and develop resistance [4]. Once a strain of HIV becomes resistant to a drug, that medication (and sometimes others in the same class) can complicate your future options [20].

Important Interactions: Integrase inhibitors commonly interact with antacids, calcium, iron, and magnesium supplements, which should be separated by several hours. Discuss all supplements like St. John’s wort, or medicines like rifampin or metformin, with your pharmacist.

If you miss a dose, take it as soon as you remember unless it is almost time for your next one; do not double up. Never stop your medication on your own without guidance. Modern pills are forgiving of an occasional late dose, but taking your pill at the same time every day is the best way to ensure your long-term health [9][4]. (Long-acting injectable ART is also an option for some people after viral suppression, provided injection appointments are strictly kept).

Common questions in this guide

Can HIV treatment start on the day I am diagnosed?
Many people can be offered antiretroviral therapy (ART) as soon as possible after an HIV diagnosis, sometimes on the same day. A clinician may first evaluate suspected severe infections such as cryptococcal or tuberculosis meningitis and review pregnancy, hepatitis B, kidney function, and prior HIV drug exposure.
How will my doctor choose my first HIV medication?
The choice depends on your kidney function, hepatitis B status, viral load, resistance results, pregnancy plans, prior exposure to integrase inhibitors, and other lab findings. Your clinician matches these factors with a regimen’s effectiveness, safety, interactions, and dosing requirements.
Is Dovato a good first treatment for everyone with HIV?
No. Dovato is generally avoided when a person has active hepatitis B, an initial viral load above 500,000 copies per milliliter, or pregnancy or plans to become pregnant without specialist guidance. A clinician should confirm that the two-drug regimen fits your medical history and test results.
Why is an HLA-B*57:01 test needed before taking Triumeq?
The HLA-B*57:01 test checks for a genetic marker linked to a severe allergic reaction to abacavir, one of Triumeq’s ingredients. People with this marker should not take abacavir-containing treatment, so the result helps guide a safer choice.
What should I do if I miss an HIV treatment dose?
Take the missed dose as soon as you remember unless it is almost time for the next dose; do not take two doses together. Ask your clinician or pharmacist for regimen-specific advice, and do not stop HIV treatment on your own.
Can antacids, vitamins, or other medicines interfere with HIV treatment?
Yes, integrase inhibitors can interact with antacids and supplements containing calcium, iron, or magnesium, and they may need to be separated by several hours. Tell your pharmacist or clinician about all medicines and supplements, including St. John’s wort, rifampin, and metformin, before starting or changing treatment.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I a candidate for a 'Rapid Start' today, or should we evaluate for opportunistic infections or wait for specific results?
  2. 2.Why is the chosen regimen better for my specific situation than other options?
  3. 3.If we are considering an abacavir-based therapy, do we have my HLA-B*57:01 test result back yet?
  4. 4.How will my other health conditions, such as kidney function or bone density, affect which NRTI 'backbone' you choose for me?
  5. 5.What should I do if I accidentally miss a dose, and what over-the-counter supplements or antacids should I avoid?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Same-day and rapid initiation of antiretroviral therapy in people living with HIV in Asia. How far have we come?

    Hung CC, Phanuphak N, Wong CS, et al.

    HIV medicine 2022; (23 Suppl 4()):3-14 doi:10.1111/hiv.13410.

    PMID: 36254390
  2. 2

    Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial.

    Gaur AH, Cotton MF, Rodriguez CA, et al.

    The Lancet. Child & adolescent health 2021; (5(9)):642-651 doi:10.1016/S2352-4642(21)00165-6.

    PMID: 34302760
  3. 3

    Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition.

    Engelman AN

    The Journal of biological chemistry 2019; (294(41)):15137-15157 doi:10.1074/jbc.REV119.006901.

    PMID: 31467082
  4. 4

    Non-integrase mechanisms for dolutegravir resistance.

    Engelman AN

    Retrovirology 2026; (23(1)).

    PMID: 42249499
  5. 5

    HIV nucleoside reverse transcriptase inhibitors.

    Amblard F, Patel D, Michailidis E, et al.

    European journal of medicinal chemistry 2022; (240()):114554 doi:10.1016/j.ejmech.2022.114554.

    PMID: 35792384
  6. 6

    Insights into HIV-1 Reverse Transcriptase (RT) Inhibition and Drug Resistance from Thirty Years of Structural Studies.

    Singh AK, Das K

    Viruses 2022; (14(5)) doi:10.3390/v14051027.

    PMID: 35632767
  7. 7

    Benefits and risks of rapid initiation of antiretroviral therapy.

    Ford N, Migone C, Calmy A, et al.

    AIDS (London, England) 2018; (32(1)):17-23 doi:10.1097/QAD.0000000000001671.

    PMID: 29112073
  8. 8

    Decreased Time From Human Immunodeficiency Virus Diagnosis to Care, Antiretroviral Therapy Initiation, and Virologic Suppression during the Citywide RAPID Initiative in San Francisco.

    Bacon O, Chin J, Cohen SE, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021; (73(1)):e122-e128 doi:10.1093/cid/ciaa620.

    PMID: 32449916
  9. 9

    Rapid initiation of antiretroviral therapy for people living with HIV.

    Mateo-Urdiales A, Johnson S, Smith R, et al.

    The Cochrane database of systematic reviews 2019; (6()):CD012962 doi:10.1002/14651858.CD012962.pub2.

    PMID: 31206168
  10. 10

    Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

    Sax PE, Pozniak A, Montes ML, et al.

    Lancet (London, England) 2017; (390(10107)):2073-2082 doi:10.1016/S0140-6736(17)32340-1.

    PMID: 28867499
  11. 11

    Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.

    Orkin C, DeJesus E, Sax PE, et al.

    The lancet. HIV 2020; (7(6)):e389-e400 doi:10.1016/S2352-3018(20)30099-0.

    PMID: 32504574
  12. 12

    Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection.

    Scott LJ

    Drugs 2020; (80(1)):61-72 doi:10.1007/s40265-019-01247-1.

    PMID: 31865558
  13. 13

    New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings.

    Dunn D, Price H, Vudriko T, et al.

    Journal of acquired immune deficiency syndromes (1999) 2021; (86(1)):98-103 doi:10.1097/QAI.0000000000002517.

    PMID: 33306565
  14. 14

    Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.

    Rolle CP, Berhe M, Singh T, et al.

    Open forum infectious diseases 2023; (10(3)):ofad101 doi:10.1093/ofid/ofad101.

    PMID: 36968959
  15. 15

    Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.

    Santevecchi BA, Miller S, Childs-Kean LM

    The Annals of pharmacotherapy 2020; (54(12)):1252-1259 doi:10.1177/1060028020933772.

    PMID: 32517480
  16. 16

    Role of Dolutegravir/Lamivudine in the Management of Pregnant People Living with HIV-1: A Narrative Review.

    Short WR, Patel P, Verdier G, et al.

    Infectious diseases and therapy 2025; (14(1)):59-80 doi:10.1007/s40121-024-01085-z.

    PMID: 39652285
  17. 17

    HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study.

    Mounzer K, Hsu R, Fusco JS, et al.

    AIDS research and therapy 2019; (16(1)):1 doi:10.1186/s12981-019-0217-3.

    PMID: 30651100
  18. 18

    A severe hypersensitivity reaction to abacavir following re-challenge.

    Todd S, Emerson CR

    International journal of STD & AIDS 2017; (28(3)):310-311 doi:10.1177/0956462416665937.

    PMID: 27530904
  19. 19

    The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV.

    Stellbrink HJ, Lazzarin A, Woolley I, Llibre JM

    HIV medicine 2020; (21 Suppl 1()):3-16 doi:10.1111/hiv.12833.

    PMID: 32017355
  20. 20

    Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe.

    de Salazar A, Viñuela L, Fuentes A, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023; (76(9)):1628-1635 doi:10.1093/cid/ciac972.

    PMID: 36571282

This page is for informational purposes only and does not constitute medical advice. Your HIV clinician and pharmacist should tailor treatment, timing, and interaction guidance to your health history.

Get notified when new evidence is published on HIV infectious disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.